Trials / Completed
CompletedNCT01892891
Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing
A Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Virobay Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
VBY-036 may treat or prevent nerve pain. This study aims to find the highest safe and tolerable dose of VBY-036 in healthy volunteers. Volunteers will be randomly selected to receive either a placebo or VBY-036 (30, 100, 300, 600 or 900 mg) once daily for seven days in a row.
Detailed description
Detailed description is noted in Brief Summary.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VBY-036 | Cathepsin S inhibitor |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2013-07-08
- Last updated
- 2013-12-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01892891. Inclusion in this directory is not an endorsement.